Heron Therapeutics Inc. (HRTX) Shares Up 2.6%
Heron Therapeutics Inc. (NASDAQ:HRTX) shares shot up 2.6% during trading on Tuesday . The company traded as high as $19.88 and last traded at $19.81, with a volume of 215,173 shares trading hands. The stock had previously closed at $19.30.
A number of research firms have recently commented on HRTX. Cowen and Company reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Saturday, July 9th. JMP Securities reissued a “buy” rating on shares of Heron Therapeutics in a research report on Friday, September 9th. Zacks Investment Research downgraded shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 3rd. Lake Street Capital reissued a “buy” rating and set a $45.00 target price on shares of Heron Therapeutics in a research report on Tuesday, September 6th. Finally, Leerink Swann reissued a “buy” rating on shares of Heron Therapeutics in a research report on Monday, June 27th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $47.70.
The firm has a 50-day moving average price of $19.45 and a 200-day moving average price of $18.92.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/heron-therapeutics-inc-hrtx-shares-up-2-6.html
Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.96) by $0.21. On average, analysts anticipate that Heron Therapeutics Inc. will post ($4.43) EPS for the current year.
In related news, insider Robert Rosen sold 100,000 shares of the stock in a transaction on Wednesday, August 10th. The stock was sold at an average price of $23.30, for a total value of $2,330,000.00. Following the completion of the transaction, the insider now owns 102,640 shares in the company, valued at approximately $2,391,512. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 20.31% of the stock is owned by corporate insiders.
Large investors have recently made changes to their positions in the company. BlackRock Group LTD raised its stake in shares of Heron Therapeutics by 174.2% in the first quarter. BlackRock Group LTD now owns 9,919 shares of the biotechnology company’s stock worth $188,000 after buying an additional 6,301 shares during the last quarter. Parametric Portfolio Associates LLC acquired a new stake in shares of Heron Therapeutics during the second quarter worth approximately $213,000. BlackRock Advisors LLC raised its stake in shares of Heron Therapeutics by 13.3% in the second quarter. BlackRock Advisors LLC now owns 15,104 shares of the biotechnology company’s stock worth $273,000 after buying an additional 1,769 shares during the last quarter. State Board of Administration of Florida Retirement System raised its stake in shares of Heron Therapeutics by 8.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 16,739 shares of the biotechnology company’s stock worth $302,000 after buying an additional 1,283 shares during the last quarter. Finally, American International Group Inc. raised its stake in shares of Heron Therapeutics by 8.1% in the second quarter. American International Group Inc. now owns 18,293 shares of the biotechnology company’s stock worth $330,000 after buying an additional 1,369 shares during the last quarter.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.